SCHEMBL11945064

SCHEMBL11945064

CCCS(=O)(=O)N1CCN(c2cnn(-c3ccccc3F)c(=O)c2OC2CCC(CC)CC2)CC1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.55
▸ GLA P06280 1/20 0.55
▸ HSD17B10 Q99714 3/20 0.46
▸ SCN9A Q15858 5/20 0.45
▸ SCN10A Q9Y5Y9 3/20 0.45
▸ MAPT P10636 1/20 0.42
▸ KMT2A Q03164 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945066 0.91 ALDH1A1 (0.49) KDM4EGLAHSD17B10SCN9ASCN10A
SCHEMBL11945063 0.90 HSD17B10 (0.44) KDM4EGLAHSD17B10SCN9ASCN10A
SCHEMBL11945056 0.89 KDM4E (0.58) KDM4EGLAHSD17B10SCN9ASCN10A
SCHEMBL17057909 0.86 SCN9A (0.38) HSD17B10SCN9ASCN10AMAPTTHRB
SCHEMBL11943942 0.85 TSHR (0.49) KDM4EHSD17B10SCN9AMAPTKMT2A
SCHEMBL17058337 0.84 SCN9A (0.36) KDM4EGLAHSD17B10SCN9ASCN10A
SCHEMBL11945080 0.83 KDM4E (0.57) KDM4EGLAHSD17B10SCN9ASCN10A
SCHEMBL17058134 0.83 SLC2A1 (0.37) KDM4EHSD17B10SCN9ASCN10AMAPT
SCHEMBL11943936 0.82 KDM4E (0.49) KDM4EGLAHSD17B10SCN9ASCN10A
SCHEMBL17058435 0.80 SLC2A1 (0.35) KDM4EHSD17B10SCN9ASCN10AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA KDM4E 1548/4885GLA 86/4885HSD17B10 1101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback